Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants.

Gaertner, Sébastien; Cordeanu, Elena-Mihaela; Mirea, Corina; Stephan, Dominique

Gaertner, Sébastien; Cordeanu, Elena-Mihaela; Mirea, Corina; Stephan, Dominique.

Afiliación

Gaertner S; Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France. Electronic address: sebastien.gaertner@chru-strasbourg.fr.
Cordeanu EM; Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.
Mirea C; Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.
Stephan D; Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.

Int J Cardiol ; 186: 141-2, 2015.

Article en En | MEDLINE | ID: mdl-25818758

Asunto(s)

Anticoagulantes/efectos adversos; Fibrilación Atrial/tratamiento farmacológico; Fenindiona/análogos & derivados; Trombosis/inducido químicamente; Vitamina K/antagonistas & inhibidores; Anciano de 80 o más Años; Electrocardiografía; Inhibidores del Factor Xa/uso terapéutico; Femenino; Humanos; Fenindiona/efectos adversos; Rivaroxabán/uso terapéutico; Trombosis/tratamiento farmacológico

Palabras clave

Atrial fibrillation; Hypercoagulable state; Stroke; Vitamin K antagonist

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fenindiona / Fibrilación Atrial / Trombosis / Vitamina K / Anticoagulantes Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Aged80 / Female / Humans Idioma: En Revista: Int J Cardiol Año: 2015 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google